KODIAK SCIENCES INC. This summer we will host an Investor R&D update. It will be both a snapshot and a point of departure. I urge you to look at Kodiak 2.0 with fresh eyes. We hope you will see a pre- commercial stage company with three phase 3 studies in progress –with three different late-phase molecules, exploring the treatment of three different diseases– all of which are on track for topline data read-outs in calendar year 2026. We hope you will recognize our strong track record of execution and our tremendous promise, even in this turbulent market. We are proud of what we accomplished in 2024. We look forward to continued strong execution in 2025. Sincerely, Victor Perlroth, M.D. Chairman of the Board and Chief Executive Officer